Mechanistic insights into targeting T cell membrane proteinase to promote islet β-cell rejuvenation in type 1 diabetes

FASEB Journal

Volumn 20, Issue 11, 2006, Pages 1793-1801

  Savinov, Alexei Y ^a   Rozanov, Dmitri V ^a   Strongin, Alex Y ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

CD44; IDDM; Monoclonal antibody; MT1 MMP

Indexed keywords

CD44 ANTIBODY; CYTOKINE ANTIBODY; HERMES ANTIGEN; INSULIN; MATRIX METALLOPROTEINASE 14; PRINOMASTAT; PROMETHAZINE; PROTEINASE; GELATINASE A; INTERSTITIAL COLLAGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL REGENERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; CD8+ T LYMPHOCYTE; CELL SURVIVAL; ENZYME ACTIVATION; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD44; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL SURVIVAL; DIABETES MELLITUS, TYPE 1; ENZYME ACTIVATION; FLOW CYTOMETRY; ISLETS OF LANGERHANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED NOD;

EID: 33748658978     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-6207com     Document Type: Article

References (41)

1. Homann, D., and von Herrath, M. (2004) Regulatory T cells and type 1 diabetes. Clin. Immunol. 112, 202-209
2. Mathis, D., Vence, L., and Benoist, C. (2001) beta-Cell death during progression to diabetes. Nature 414, 792-798
3. DeGrendele, H. C., Estess, P., and Siegelman, M. H. (1997) Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278, 672-675
4. Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I., and Seiki, M. (2002) CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 21, 3949-3959
5. Nakamura, H., Suenaga, N., Taniwaki, K., Matsuki, H., Yonezawa, K., Fujii, M., Okada, Y., and Seiki, M. (2004) Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. 64, 876-882
6. Suenaga, N., Mori, H., Itoh, Y., and Seiki, M. (2005) CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 24, 859-868
7. Annabi, B., Bouzeghrane, M., Currie, J. C., Hawkins, R., Dulude, H., Daigneault, L., Ruiz, M., Wisniewski, J., Garde, S., Rabbani, S. A., Panchal, C., Wu, J. J., and Beliveau, R. (2005) A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin. Exp. Metastasis 22, 429-439
8. Holmbeck, K., Bianco, P., Yamada, S., and Birkedal-Hansen, H. (2004) MT1-MMP: a tethered collagenase. J. Cell. Physiol. 200, 11-19
9. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174
10. Sabeh, F., Ota, I., Holmbeck, K., Birkedal-Hansen, H., Soloway, P., Balbin, M., Lopez-Otin, C., Shapiro, S., Inada, M., Krane, S., Allen, E., Chung, D., and Weiss, S. J. (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167, 769-781
11. Itoh, Y., and Seiki, M. (2006) MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 206, 1-8
12. Belkin, A. M., Akimov, S. S., Zaritskaya, L. S., Ratnikov, B. I., Deryugina, E. I., and Strongin, A. Y. (2001) Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J. Biol. Chem. 276, 18415-18422
13. Deryugina, E. I., Ratnikov, B. I., Postnova, T. I., Rozanov, D. V., and Strongin, A. Y. (2002) Processing of integrin alpha (v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J. Biol. Chem. 277, 9749-9756
14. Rozanov, D. V., Hahn-Dantona, E., Strickland, D. K., and Strongin, A. Y. (2004) The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J. Biol. Chem. 279, 4260-4268
15. Savinov, A. Y., Rozanov, D. V., Golubkov, V. S., Wong, F. S., and Strongin, A. Y. (2005) Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. J. Biol. Chem. 280, 27755-27758
16. Wong, F. S., Karttunen, J., Dumont, C., Wen, L., Visintin, I., Pilip, I. M., Shastri, N., Pamer, E. G., and Janeway, C. A., Jr. (1999) Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5, 1026-1031
17. Wong, F. S., Visintin, I., Wen, L., Flavell, R. A., and Janeway, C. A., Jr. (1996) CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183, 67-76
18. Hande, K. R., Collier, M., Paradiso, L., Stuart-Smith, J., Dixon, M., Clendeninn, N., Yeun, G., Alberti, D., Binger, K., and Wilding, G. (2004) Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin. Cancer Res. 10, 909-915
19. Zucker, S., Cao, J., and Chen, W. T. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650
20. Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C. D., Forsyth, P., Edwards, D., Margosiak, S., Bender, S., Truitt, G., and Wood, A., et al. (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N. Y. Acad. Sci. 878, 236-270
21. Savinov, A. Y., Wong, F. S., Stonebraker, A. C., and Chervonsky, A. V. (2003) Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J. Exp. Med. 197, 643-656
22. Traisman, H. S., and Greenwood, R. D. (1973) A comparative clinical evaluation of a new proprietary method for urine testing in juvenile diabetics. Clin. Pediatr. 12, 357-359
23. Pomerleau, D. P., Bagley, R. J., Serreze, D. V., Mathews, C. E., and Leiter, E. H. (2005) Major histocompatibility complex-linked diabetes susceptibility in NOD/Lt mice: subcongenic analysis localizes a component of Idd16 at the H2-D end of the diabetogenic H2(g7) complex. Diabetes 54, 1603-1606
24. Savinov, A. Y., Wong, F. S., and Chervonsky, A. V. (2001) IFN-gamma affects homing of diabetogenic T cells. J. Immunol. 167, 6637-6643
25. Deryugina, E. I., Ratnikov, B., Monosov, E., Postnova, T. I., DiScipio, R., Smith, J. W., and Strongin, A. Y. (2001) MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 263, 209-223
26. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331-5338
27. Ablamunits, V., Elias, D., and Cohen, I. R. (1999) The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse. Clin. Exp. Immunol. 115, 260-267
28. Weiss, L., Slavin, S., Reich, S., Cohen, P., Shuster, S., Stern, R., Kaganovsky, E., Okon, E., Rubinstein, A. M., and Naor, D. (2000) Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 97, 285-290
29. Ezaki, T., Baluk, P., Thurston, G., La Barbara, A., Woo, C., and McDonald, D. M. (2001) Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am. J. Pathol. 158, 2043-2055
30. Will, H., Atkinson, S. J., Butler, G. S., Smith, B., and Murphy, G. (1996) The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 271, 17119-17123
31. Amour, A., Knight, C. G., Webster, A., Slocombe, P. M., Stephens, P. E., Knauper, V., Docherty, A. J., and Murphy, G. (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275-279
32. Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knauper, V., Docherty, A. J., and Murphy, G. (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435, 39-44
33. Lee, M. H., Maskos, K., Knauper, V., Dodds, P., and Murphy, G. (2002) Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Prot. Sci. 11, 2493-2503
34. Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., and Seiki, M. (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893-904
35. Luo, X., Yang, H., Kim, I. S., Saint-Hilaire, F., Thomas, D. A., De, B. P., Ozkaynak, E., Muthukumar, T., Hancock, W. W., Crystal, R. G., and Suthanthiran, M. (2005) Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 79, 1091-1096
36. Bissett, D., O'Byrne, K. J., von Pawel, J., Gatzemeier, U., Price, A., Nicolson, M., Mercier, R., Mazabel, E., Penning, C., and Zhang, M. H., et al. (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 23, 842-849
37. Griffioen, A. W. (2000) AG-3340 (Agouron Pharmaceuticals Inc.). IDrugs 3, 336-345
38. Zhou, Y. P., Madjidi, A., Wilson, M. E., Nothhelfer, D. A., Johnson, J. H., Palma, J. F., Schweitzer, A., Burant, C., Blume, J. E., and Johnson, J. D. (2005) Matrix metalloproteinases contribute to insulin insufficiency in Zucker diabetic fatty rats. Diabetes 54, 2612-2619
39. Chong, A. S., Shen, J., Tao, J., Yin, D., Kuznetsov, A., Hara, M., and Philipson, L. H. (2006) Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311, 1774-1775
40. Nishio, J., Gaglia, J. L., Turvey, S. E., Campbell, C., Benoist, C., and Mathis, D. (2006) Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311, 1775-1778
41. Suri, A., Calderon, B., Esparza, T. J., Frederick, K., Bittner, P., and Unanue, E. R. (2006) Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 311, 1778-1780